Finasteride monotherapy maintains stable lower urinary tract symptoms in men with benign prostatic hyperplasia following cessation of alpha blockers

Journal of the Canadian Urological Association

Volumn 2, Issue 1, 2008, Pages 16-21

  Nickel, J Curtis ^a   Barkin, Jack ^b   Koch, Caroline ^c   Dupont, Charles ^d   Elhilali, Mostafa ^e  

^a QUEEN S UNIVERSITY   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c MERCK FROSST CENTRE FOR THERAPEUTIC RESEARCH   (Canada)

^d Data Med Inc   (Canada)

^e MONTREAL GENERAL HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 63149140375     PISSN: 19116470     EISSN: 19116470     Source Type: Journal    
DOI: 10.5489/cuaj.520     Document Type: Article

References (11)

1. McConnell JD, Roehrborn CG, Bautista OM, et al. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med 2003;349:2387-2398.
2. Andersson KE. Storage and voiding symptoms: pathophysiologic aspects. Urology 2003;62(Suppl 2):3-10.
3. Marks LS, Partin AW, Dorey FJ, et al. Long-term effects of finasteride on prostate tissue composition. Urology 1999;53:574-580.
4. Roehrborn CG. 5-alpha-Reductase inhibitors prevent the progression of benign prostatic hyperplasia. Rev Urol 2003;5(Suppl 5):S12-21.
5. Madersbacher S, Marszalek M, Lackner J, et al. The long-term outcome of medical therapy for BPH. Eur Urol 2007;51:1522-1533
6. Baldwin KC, Ginsberg PC, Harkaway RC. Discontinuation of alpha-blockade after initial treatment with finasteride and doxazosin for bladder outlet obstruction. Urol Int 2001;66:84-88
7. Baldwin KC, Ginsberg PC, oehrborn CG, et al. Discontinuation of alpha-blockade after initial treatment with finasteride and doxazosin in men with lower urinary tractsymptoms and clinical evidence of benign prostatic hyperplasia. Urology 2001;58:203-209.
8. Barkin J, Guimaraes M, Joacobi G, et al. Alpha-blocker therapy can be withdrawn in the majority of men following initial combination therapy with the dual 5alpha-reductase inhibitor dutasteride. Eur Urol 2003;44:461-466.
9. Barry MJ, Williford WO, Chang Y, et al. Benign prostatic hyperplasia specific health status measures in clinical research: how much change in the American Urological Association symptom index and the benign prostatic hyperplasia impact index is perceptible to patients? J Urol 1995;154:1770-1774.
10. Kirby RS, Roehrborn C, Boyle P, et al. Efficacy and tolerability of doxazosin and finasteride, alone or in combination, in treatment of symptomatic benign prostatic hyperplasia: the Prospective European Doxazosin and Combination Therapy (PREDICT) trial. Urology 2003;61:119-126.
11. Lepor H, Williford WO, Barry MJ, et al. The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasia Study Group. N Engl J Med 1996;335:533-539.